The following summarizes published research
As with any research compound, careful protocol design, observation, and adherence to ethical guidelines are paramount
At BCDiabetes we do so by giving 1.0 mg more frequently than weekly
They quiet the noise in your brain. The recent study published in Nature Medicine found that GLP-1 use was associated with a reduced risk of several substance-related disorders, including alcohol-use disorders, cannabis-use disorders, stimulant-use disorders and opioid-use disorders
In large randomized trials of FDA-approved branded semaglutide, once-weekly treatment alongside lifestyle intervention produced substantial average weight loss over 68 weeks (Wilding et al., 2021), with continued treatment supporting weight maintenance (Rubino et al., 2021)
According to NICE Technology Appraisal 875 (TA875) , Wegovy (semaglutide) is available on the NHS only through specialist weight management services and for adults who meet specific criteria, including: Generally, a body mass index (BMI) of 35 kg/m or greater with weight-related comorbidities (with lower thresholds for certain ethnic groups) Referral to and engagement with a specialist weight management service (Tier 3) Treatment limited to a maximum of 2 years This differs from the broader marketing authorisation criteria in the SmPC, which includes adults with a BMI of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbidities